In the present study, ψ-Bufarenogin repressed EpCAM, CD90, and CD133 expression and diminished hepatoma T-ICs in HCC cell line and primary hepatoma cells of patients. This evidence concerns the gene PROM1 and hepatocellular carcinoma.